VOICED : Hidrocortisona reduce la mortalidad de enfermos graves de coronavirus, según un estudio

Hydrocortisone, a low-cost steroid, reduces the risk of death by about 20% in severe COVID-19 cases. The British healthcare system plans to use it following a study led by Anthony Gordon from Imperial College London. The study showed improved survival and faster recovery in patients treated with steroids. Tests on 403 patients across 88 UK hospitals revealed hydrocortisone's efficacy, potentially saving one in 12 patients. Without it, 40% of severe cases resulted in death, compared to 32% with treatment. Hydrocortisone helps reduce lung and body inflammation but is not for home use or mild cases. The NHS announced immediate measures to ensure eligible patients receive this treatment.

What is the primary benefit of using hydrocortisone in severe COVID-19 cases?

• It reduces the risk of death by about 20%.

• It prevents the infection entirely.

• It cures COVID-19 completely.

• It is a vaccine for COVID-19.

Who is Anthony Gordon in the context of the hydrocortisone study?

• A patient who recovered from COVID-19.

• A journalist reporting on the study.

• A researcher at Imperial College London.

• A government official implementing health policies.

How many different steroids were tested in the study mentioned?

• Five

• Ten

• Twelve

• Seven

What percentage of patients died in the group that did not receive hydrocortisone?

• 32%

• 50%

• 60%

• 40%

What is a key point about the use of hydrocortisone for COVID-19 treatment?

• It can be used at home to prevent infection.

• It is effective for mild viral infections.

• It is a substitute for vaccines.

• It is not for home use or mild infections.